Design Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	-	16.86	22.56	21.2	26.5	298.57
Short-Term Investments	-	202.99	222.91	260.6	303.89	85.5
Cash & Short-Term Investments	-	219.85	245.48	281.8	330.39	384.06
Cash Growth	-	-10.44%	-12.89%	-14.71%	-13.98%	964.15%
Other Current Assets	4.62	3.94	2.56	2.79	4.73	1.37
Total Current Assets	212.01	223.78	248.04	284.58	335.12	385.44
Net Property, Plant & Equipment	3.12	2.42	3.63	4.63	5.56	5.12
Other Long-Term Assets	-	-	0.43	0.43	0.46	-
Total Assets	215.13	226.2	252.09	289.64	341.14	390.56
Accounts Payable	3.14	2.31	2.19	1.94	3.03	1.62
Accrued Expenses	8.1	10.74	6.28	7.68	7.75	3.66
Total Current Liabilities	11.24	13.06	8.46	9.62	10.78	5.28
Long-Term Leases	2.03	0.65	1.53	2.33	3.05	3.14
Total Long-Term Liabilities	2.03	0.65	1.53	2.33	3.05	3.14
Total Liabilities	13.27	13.7	10	11.96	13.83	8.43
Common Stock	-	0.01	0.01	0	0.01	0.01
Additional Paid-in Capital	-	509.1	468.83	455.25	441.42	429.82
Accumulated Other Comprehensive Income	-	0.4	0.48	0.06	-3.36	-0.24
Retained Earnings	-	-297.01	-227.21	-177.63	-110.76	-47.46
Total Common Shareholders' Equity	201.86	212.5	242.1	277.69	327.31	382.13
Shareholders' Equity	201.86	212.5	242.1	277.69	327.31	382.13
Total Liabilities & Equity	215.13	226.2	252.09	289.64	341.14	390.56
Total Debt	2.03	0.65	1.53	2.33	3.05	3.14
Net Cash (Debt)	-2.03	219.2	243.94	279.46	327.34	380.92
Net Cash Growth	-	-10.14%	-12.71%	-14.63%	-14.07%	955.44%
Net Cash Per Share	-0.03	3.82	4.31	4.99	5.88	8.29
Book Value	201.86	212.5	242.1	277.69	327.31	382.13
Book Value Per Share	3.37	3.71	4.28	4.96	5.88	8.32
Tangible Book Value	201.86	212.5	242.1	277.69	327.31	382.13
Tangible Book Value Per Share	3.37	3.71	4.28	4.96	5.88	8.32

SEC Filings: 10-K · 10-Q